EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Apr 2012. 401 kB.
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #2. AM-1220 azepane isomer
Yoshida, M; Suzuki, J; Nakajima, J; Nagashima, M; Takahashi, M; Uemura, N; Kanai, C; Moriyasu, T; Hamano, T; Nakae, D. Analysis of illegal drugs purchased in the fiscal year 2011. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2012, 63 111–124. 575 kB. #AM1220-azepanindol MS,NMR,UV
Nakajima, J; Takahashi, M; Seto, T; Kanai, C; Suzuki, J; Yoshida, M; Uemura, N; Hamano, T. Analysis of azepane isomers of AM-2233 and AM-1220, and detection of an inhibitor of fatty acid amide hydrolase [3′-(aminocarbonyl)(1,1′-biphenyl)-3-yl]-cyclohexylcarbamate (URB597) obtained as designer drugs in the Tokyo area. Forensic Toxicol., 10 Nov 2012, 31 (1), 76–85. 561 kB. https://doi.org/10.1007/s11419-012-0169-y #4 LC,MS,NMR,UV
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #114